Literature DB >> 12021521

Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure.

Tsutomu Sanaka1, Takenori Funaki, Toshihisa Tanaka, Sayako Hoshi, Jyun Niwayama, Takashi Taitoh, Hideki Nishimura, Chieko Higuchi.   

Abstract

The plasma pentosidine levels in patients with renal disease were measured by a simple method which was established for plasma and urinary pentosidine determinations. The method, which can be completed within a few hours, involves pretreating plasma with proteolytic enzyme (pronase) and measuring the concentration of pentosidine in the sample by ELISA using antipentosidine antibodies. The prepared antibodies showed no cross-reaction with the raw materials for pentosidine synthesis or with compounds having similar structures. SDS-PAGE indicated that the antibodies had a high purity. The reaction of the antibodies and keyhole limpet hemocyanin-pentosidine in the competitive ELISA system was inhibited by free pentosidine. Excellent standard curves for pentosidine determination were obtained. In actual measurements of clinical samples from patients, a good correlation (r = 0.9356) was obtained between the values measured by ELISA and HPLC. The plasma pentosidine level in patients with renal disease correlated significantly with plasma creatinine, urea nitrogen, beta2-microglobulin, and creatinine clearance, indicating its usefulness in evaluating the severity of renal disease. A significant elevation in plasma pentosidine levels was observed in mild renal dysfunction, whereas no significant increases in creatinine and urea nitrogen levels were detected, suggesting that the plasma pentosidine level is useful in the early diagnosis of beginning renal failure. In patients with chronic renal failure, no difference in plasma pentosidine levels was observed between diabetic nephropathy and chronic glomerulonephritis, while a significant correlation was observed with phosphatidylcholine hydroperoxide, suggesting the possibility that the plasma pentosidine level reflects injury due to oxidation. From these results, the quantitative measurement method developed by us is judged to be a superior innovation for measuring pentosidine in body fluids. The plasma pentosidine level may be useful for the early diagnosis of mild renal failure and to estimate the degree of the severity of renal diseases. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021521     DOI: 10.1159/000057606

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  16 in total

Review 1.  Antibody-based detection of advanced glycation end-products: promises vs. limitations.

Authors:  Ryoji Nagai; Jun-Ichi Shirakawa; Rei-Ichi Ohno; Kota Hatano; Hikari Sugawa; Shoutaro Arakawa; Kenta Ichimaru; Shoh Kinoshita; Noriyuki Sakata; Mime Nagai
Journal:  Glycoconj J       Date:  2016-07-15       Impact factor: 2.916

Review 2.  Pathways of the Maillard reaction under physiological conditions.

Authors:  Christian Henning; Marcus A Glomb
Journal:  Glycoconj J       Date:  2016-06-13       Impact factor: 2.916

3.  Significance of measurements of peripheral carbonyl stress markers in a cross-sectional and longitudinal study in patients with acute-stage schizophrenia.

Authors:  Narimasa Katsuta; Tohru Ohnuma; Hitoshi Maeshima; Yuto Takebayashi; Motoyuki Higa; Mayu Takeda; Toru Nakamura; Shohei Nishimon; Takahiro Sannohe; Yuri Hotta; Ryo Hanzawa; Ryoko Higashiyama; Nobuto Shibata; Heii Arai
Journal:  Schizophr Bull       Date:  2014-01-21       Impact factor: 9.306

4.  The association of urinary pentosidine levels with the prevalence of osteoporotic fractures in postmenopausal women.

Authors:  Masataka Shiraki; Shoji Kashiwabara; Takumi Imai; Shiro Tanaka; Mitsuru Saito
Journal:  J Bone Miner Metab       Date:  2019-06-18       Impact factor: 2.626

5.  Reduction of plasma asymmetric dimethylarginine in obese patients with chronic kidney disease after three years of a low-protein diet supplemented with keto-amino acids: a randomized controlled trial.

Authors:  Vladimir Teplan; Otto Schück; Jaroslav Racek; Olga Mareckova; Milena Stollova; Vladimir Hanzal; Jan Malý
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

6.  Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis.

Authors:  Richard Vytásek; Liliana Sedová; Vladimír Vilím
Journal:  BMC Musculoskelet Disord       Date:  2010-05-03       Impact factor: 2.362

7.  Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study.

Authors:  E Gineyts; F Munoz; C Bertholon; E Sornay-Rendu; R Chapurlat
Journal:  Osteoporos Int       Date:  2009-05-07       Impact factor: 4.507

8.  Prevalence and progression of radiographic ossification of the posterior longitudinal ligament and associated factors in the Japanese population: a 3-year follow-up of the ROAD study.

Authors:  N Yoshimura; K Nagata; S Muraki; H Oka; M Yoshida; Y Enyo; R Kagotani; H Hashizume; H Yamada; Y Ishimoto; M Teraguchi; S Tanaka; H Kawaguchi; Y Toyama; K Nakamura; T Akune
Journal:  Osteoporos Int       Date:  2013-08-22       Impact factor: 4.507

Review 9.  Detection of AGEs as markers for carbohydrate metabolism and protein denaturation.

Authors:  Ryoji Nagai; Jun-Ichi Shirakawa; Yukio Fujiwara; Rei-Ichi Ohno; Narumi Moroishi; Noriyuki Sakata; Mime Nagai
Journal:  J Clin Biochem Nutr       Date:  2014-07-01       Impact factor: 3.114

10.  Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes.

Authors:  Masahiro Yamamoto; Toru Yamaguchi; Mika Yamauchi; Toshitsugu Sugimoto
Journal:  Diabetes Care       Date:  2009-09-14       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.